The First global, head-to-head trial comparing second- and rst-generation EGFR-directed therapies (afatinib* and getinib respectively) in the first-line treatment of patients with EGFR mutation-positive NSCLC

*Afatinib is approved in a number of markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF^®, in the US under the brand name GILOTRIF^® and in India under the brand name XOVOLTIB^® for use in patients withdistinct types of EGFR mutation-positive NSCLC. Afatinib is under regulatory review by health authorities in other countries worldwide. Registration conditions differ internationally, please refer to locally approved prescribing information.
1. Park et al. Afatinib versus getinib as rst-line treatment for patients with advanced non-small cell lung cancer harboring activating EGFR mutations: results of the global, randomized, open-label, Phase IIb trial LUX-Lung 7. LBA2,oral presentation at the ESMO Asia 2015 Congress in Singapore, 18–21 December 2015. ^© 2015 Boehringer Ingelheim GmbH. All rights reserved | Last updated: January 2016